Loading...
Bilateral Trade Intelligence · $22.7M Total Trade · 94 Exporters · 170 Buyers · DGFT Verified · Updated March 2026
India exported $22.7M worth of pharmaceutical formulations to Israel across 1,068 verified shipments, sourced from 94 Indian exporters supplying 170 Israel buyers. The top exporters are MEDOPHARM ($9.5M) and AUROBINDO PHARMA LTD ($3.8M). The leading products are Amoxicillin ($8.9M) and Bortezomib ($246K). Average shipment value: $21.3K.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Amoxicillin and Clavulanate Potassium Fo | $8.9M | 39.0% |
| 2 | Amoxicillin & Clavulanate Potassiumtable | $983.8K | 4.3% |
| 3 | Compresso Pap 96p | $404.9K | 1.8% |
| 4 | Dtp-hepb-hib (pentavalent Vaccine) Fullyliquid Combination Vaccine 10 Dose Vial… | $340.5K | 1.5% |
| 5 | Bortezomib Taro Injection 3.5mg | $246.5K | 1.1% |
| 6 | Bortezomibe Medomie 3.5mg (1 Vial) Medomie Pharma | $194.6K | 0.9% |
| 7 | Dtp-hepb-hib (pentavalent Vaccine) Fullyliquid Combination Vaccine 10dose (5ml)… | $173.8K | 0.8% |
| 8 | Bezafibrate 400mg Sr Tablets 3x10s (57760 Packs)kgs | $158.8K | 0.7% |
| 9 | Amoxicillin & Clavulanate Potassium Tablets 1000 MG 14's(qty:89098 Pac) | $157.1K | 0.7% |
| 10 | Amoxicillin & Clavulanate Potassium Tablets 1000 MG 14's(qty- 88810 Pac) | $156.5K | 0.7% |
| 11 | Amoxicillin & Clavulanate Potassium Tablets 1000 MG 14's(qty- 88720 Pac) | $156.3K | 0.7% |
| 12 | Amoxicillin & Clavulanate Potassium Tablets 1000 MG 14's(qty:88594 Pac) | $156.2K | 0.7% |
| 13 | Amoxicillin & Clavulanate Potassium Tablets 1000 MG 14's(qty:88378pac) | $155.8K | 0.7% |
| 14 | Bezafibrate 400mg Sr Tablets Bezafibrate Medomie 400mg 3x10s 57280 | $154.9K | 0.7% |
| 15 | Ph.dru.& Med.: Stimopeg 6mg/0.6ml 1 Pfs | $150.0K | 0.7% |
India exports 20+ pharmaceutical formulations to Israel with a combined trade value of $22.7M. Key products include Amoxicillin ($8.9M), Bortezomib ($246K), Potassium ($157K), Ramipril ($140K), Meropenem ($138K). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 1,068 verified Indian Customs (DGFT) shipment records.
Historical evolution, India's market position, and recent developments
The India-Israel pharmaceutical trade corridor has experienced significant growth over the past two decades. In 2001–02, India's pharmaceutical exports to Israel were approximately $428 million. This figure steadily increased, reaching $4 billion in 2011–12 and peaking at $8.49 billion in 2022–23. However, recent years have seen a decline, with exports dropping to $4.5 billion in 2023–24 and further to about $2.1 billion in 2024–25.
The decline in exports during 2023–25 can be attributed to various factors, including global economic fluctuations and shifts in demand. Despite this downturn, the pharmaceutical sector remains a vital component of bilateral trade. In the fiscal year 2024–25, total merchandise trade between India and Israel stood at $3.62 billion, with the pharmaceutical sector contributing significantly to this figure.
India's pharmaceutical exports to Israel amounted to $14.54 million in 2024, while Israel's pharmaceutical exports to India were $13.02 million in the same year. This indicates a balanced trade relationship in the pharmaceutical sector, with India slightly ahead in exports. The strategic importance of this corridor is underscored by the ongoing negotiations for a Free Trade Agreement (FTA), which aim to enhance trade and economic cooperation between the two nations.
These are the top pharmaceutical products exported from India to Israel, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Israel buyers, regulatory requirements, and logistics for that specific product corridor. Products include Amoxicillin ($8.9M), Bortezomib ($246K), Potassium ($157K), Ramipril ($140K), Meropenem ($138K) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
94 Indian pharmaceutical companies export finished formulations to Israel. Leading exporters include Medopharm, Aurobindo Pharma Ltd, Jubilant Generics Limited, Msn Laboratories Private Limited. The top exporter accounts for 41.9% of total India–Israel pharma exports. Source: Indian Customs (DGFT).
170 companies in Israel import pharmaceutical formulations from India. Top buyers include M/s. Unrwa - Head Field Logistics O, Teva Israel Ltd,, Inovamed Ltd,, Inovamed Ltd. The largest buyer accounts for 38.8% of India–Israel pharma imports. Source: Indian Customs (DGFT).
In February 2026, India and Israel commenced the first round of negotiations for a Free Trade Agreement (FTA) in New Delhi, scheduled from February 23 to 26. The Terms of Reference (ToR) for these negotiations were signed in November 2025, establishing a structured framework to enhance trade and economic cooperation. The FTA negotiations cover various aspects, including trade in goods and services, rules of origin, sanitary and phytosanitary measures, technical barriers to trade, customs procedures, trade facilitation, and intellectual property rights.
The FTA is expected to provide greater certainty and predictability for businesses, including micro, small, and medium enterprises (MSMEs), thereby further boosting bilateral trade. The successful conclusion of these negotiations is anticipated to strengthen the pharmaceutical trade corridor between India and Israel, fostering deeper economic ties and collaboration in the sector.
Registration process, GMP requirements, import documentation
To market pharmaceutical products in Israel, Indian companies must register their finished formulations with the Israeli Ministry of Health's Pharmaceutical Division. The registration process involves submitting a comprehensive dossier that includes:
The evaluation period for registration varies based on the product's regulatory history. For generics, the process typically takes 120 working days from receipt of the application to the issuance of a registration certificate or rejection letter.
The dossier should be compiled in accordance with the Common Technical Document (CTD) format, which is internationally recognized and facilitates the review process. While the CTD is the standard, the Pharmaceutical Division may accept other formats if they meet the necessary requirements. (gov.il)
Israeli regulations require that manufacturing facilities comply with Good Manufacturing Practice (GMP) standards to ensure the quality and safety of pharmaceutical products. For foreign manufacturers, GMP certification from recognized authorities such as the FDA, EMA, or WHO is typically accepted. The Pharmaceutical Division may conduct inspections or request additional documentation to verify compliance. Notably, Israel has an Agreement on Conformity Assessment and Acceptance of Industrial Products (ACAA) with the European Union, which recognizes GMP certificates issued by either party.
To import pharmaceutical products into Israel, companies must obtain an import permit from the Ministry of Health. The application requires:
Applications are processed within 21 business days. (gov.il)
Additionally, for controlled substances, separate import or export approvals must be requested for each type of material, and applications are processed within 21 working days. (gov.il)
Dominant categories, emerging opportunities, and demand drivers
India's pharmaceutical exports to Israel are predominantly concentrated in the anti-infective therapeutic category, particularly in antibiotics. The leading product, Amoxicillin and Clavulanate Potassium in both powder for oral suspension and tablet forms, accounts for approximately 39% of the total export value. This dominance aligns with Israel's healthcare needs, as antibiotics are essential in treating a wide range of bacterial infections. The substantial demand for these medications underscores the critical role they play in Israel's healthcare system.
Additionally, vaccines, notably the DTP-HepB-Hib (Pentavalent Vaccine), represent a significant portion of exports, reflecting Israel's commitment to immunization programs. The inclusion of oncology treatments, such as Bortezomib injections, indicates a growing focus on addressing complex diseases within the Israeli market. These therapeutic areas are pivotal in meeting the diverse healthcare requirements of the Israeli population.
The Israeli pharmaceutical market is experiencing a shift towards biosimilars, driven by regulatory changes aimed at enhancing the availability of cost-effective biologic treatments. In December 2023, Israel's Ministry of Health revised its guidelines to facilitate the registration and use of biosimilars, indicating a more lenient approach to their integration into the market. (rcip.co.il) This regulatory shift presents opportunities for Indian pharmaceutical companies to export biosimilars to Israel, capitalizing on the demand for affordable biologic therapies.
Furthermore, the global trend towards complex generics and biosimilars is mirrored in Israel, with companies like Teva Pharmaceutical Industries Ltd. leading in biosimilar development. This environment creates avenues for Indian exporters to collaborate and supply complex generics and biosimilars, meeting the evolving needs of the Israeli market.
Israel's healthcare system is characterized by a centralized market dominated by Health Management Organizations (HMOs), which conduct large-scale generic medication tenders. This structure emphasizes cost-effectiveness and efficiency in pharmaceutical procurement. The increasing prevalence of chronic diseases, such as cardiovascular conditions, diabetes, and cancer, coupled with an aging population, is driving the demand for affordable and effective medications. The government's support for generic drugs, including policies that foster competition and innovation, further contributes to the growing demand for pharmaceutical imports. These factors collectively underscore the expanding opportunities for Indian pharmaceutical companies to meet Israel's evolving healthcare needs.
Tariff structure, trade agreements, IP and patent landscape
As of March 2026, Israel's Most-Favored-Nation (MFN) tariff rates for pharmaceutical products classified under HS codes 3003 and 3004 are generally set at zero percent. This means that, in the absence of specific trade agreements, pharmaceutical imports from countries like India would enter Israel duty-free. However, it's important to note that these rates can be subject to change based on bilateral agreements or policy adjustments.
Regarding preferential duty rates, India and Israel have initiated negotiations for a Free Trade Agreement (FTA) as of February 2026. The first round of these negotiations took place in New Delhi from February 23 to 26, 2026. While the specific details of the FTA, including any preferential duty rates for pharmaceutical products, have not been finalized, the agreement aims to enhance trade relations and may lead to further reductions or eliminations of tariffs on pharmaceutical imports.
India and Israel have been engaged in FTA negotiations since 2006, with discussions resuming in November 2025 after a decade-long pause. The renewed focus on the FTA reflects a strategic shift towards deeper economic cooperation, particularly in sectors like defense manufacturing and precision agriculture. While merchandise trade remains modest, the FTA is expected to provide a framework for increased collaboration and potential tariff reductions, benefiting industries such as pharmaceuticals.
Israel's intellectual property (IP) framework is aligned with international standards, including the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement. This alignment means that patent protections in Israel are robust, potentially affecting the entry of generic drugs from India. However, Israel's IP laws also provide mechanisms for compulsory licensing under specific conditions, which could allow for the importation of generic drugs if certain criteria are met. The ongoing FTA negotiations may address IP provisions, potentially introducing safeguards for generic drug imports to ensure a balance between patent rights and public health needs.
Shipping routes, port infrastructure, cold chain compliance
Pharmaceutical shipments from India to Israel primarily utilize both sea and air freight, each offering distinct advantages. Sea freight is cost-effective for bulk shipments but involves longer transit times, typically ranging from 18 to 22 days, depending on the specific ports and shipping conditions. Air freight, while more expensive, provides faster delivery, often within 2 to 4 days, making it suitable for urgent or high-value pharmaceutical products.
The Red Sea, a critical maritime route for shipments from Indian ports to Israel, has experienced disruptions due to geopolitical tensions and natural events. Such disruptions can lead to increased transit times and costs, necessitating alternative routing or scheduling adjustments. For instance, in July 2025, a significant blockage in the Suez Canal, a key passage connecting the Red Sea to the Mediterranean, resulted in a backlog of maritime traffic, affecting global shipping schedules. Shippers must monitor such developments closely to mitigate potential impacts on delivery timelines.
In India, key export ports handling pharmaceutical shipments include Chennai Air, Hyderabad ICD, and Hyderabad ICD (INSNF6). Chennai Air, accounting for 1.0% of shipments, serves as a significant air cargo hub. Hyderabad ICD, with 3.8% of shipments, and Hyderabad ICD (INSNF6), at 1.2%, are important inland container depots facilitating efficient cargo movement.
In Israel, major import ports for pharmaceutical products are Ashdod (19.3%), Tel Aviv Yafo (45.3%), and Haifa (13.4%). Tel Aviv Yafo, handling the largest share, is a central hub for both sea and air freight, offering advanced facilities for pharmaceutical imports. Ashdod and Haifa ports are equipped with specialized infrastructure to manage pharmaceutical cargo, ensuring compliance with international standards.
Maintaining the integrity of temperature-sensitive pharmaceutical products during transit from India to Israel is paramount. These products, including vaccines and biologics, require strict temperature control, typically between 2°C and 8°C, to preserve their efficacy and safety. To ensure compliance with Good Distribution Practice (GDP) guidelines, shipments must be equipped with validated packaging solutions, such as insulated containers and temperature data loggers, to monitor and record conditions throughout the journey. Additionally, adherence to the World Health Organization's Good Manufacturing Practice (WHO-GMP) standards is essential for regulatory compliance in Israel. Failure to maintain the cold chain can result in product degradation, regulatory penalties, and potential health risks.
Market size, healthcare system, growth outlook
Israel's pharmaceutical market was valued at approximately $1.75 billion in 2015 and is projected to reach $2.12 billion by 2020, reflecting a compound annual growth rate (CAGR) of 3.9%. The market is characterized by a strong emphasis on research and development (R&D), positioning Israel as the fourth-largest supplier of pharmaceutical products globally. This growth is driven by the rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders, which necessitate advanced pharmaceutical solutions.
The generic drug segment plays a significant role in Israel's pharmaceutical market. Generic drugs account for 15%-20% of the sales in Israel, contributing to annual savings of approximately $500 million. This substantial market share underscores the importance of generics in the country's healthcare system.
Israel's healthcare system operates under the National Health Insurance Law (NHIL), enacted in 1995, which mandates universal health insurance for all citizens and permanent residents. This system ensures that all individuals have access to a comprehensive range of medical services, including pharmaceuticals. The government actively promotes the use of generic drugs to control healthcare expenditures, leading to high substitution rates and significant savings.
The Ministry of Health's Pharmaceutical Administration oversees the importation and approval of pharmaceutical products, ensuring compliance with EU Good Manufacturing Practice (GMP) regulations. This regulatory framework maintains high standards for drug quality and safety, fostering a reliable environment for pharmaceutical imports.
The Indian pharmaceutical export to Israel has demonstrated steady growth, with a total export value of $22.7 million USD over 1,068 shipments from 94 Indian exporters to 170 Israeli buyers. The average shipment value is approximately $21,000, indicating a robust trade relationship. The top products exported include amoxicillin and clavulanate potassium formulations, accounting for 39% of the total export value.
Given Israel's strong emphasis on generic drugs, there is a significant opportunity for Indian exporters to expand their presence in this segment. The rising prevalence of chronic diseases in Israel further drives the demand for affordable and effective pharmaceutical solutions, aligning with India's capabilities in producing high-quality generics. Additionally, the Israeli government's supportive policies towards generic drug adoption create a favorable environment for Indian pharmaceutical companies to increase their market share.
Competing origins, India's edge, challenges and threats
Israel's pharmaceutical market is diverse, with suppliers from various regions, including China, the European Union (EU), domestic manufacturers, and other emerging markets. China has been expanding its presence in Israel, offering a range of pharmaceutical products at competitive prices. EU manufacturers, particularly those from Germany and Switzerland, are known for high-quality standards and have established a significant foothold in the Israeli market. Domestically, Israel's pharmaceutical industry is robust, with companies like Teva Pharmaceutical Industries Ltd., Taro Pharmaceutical Industries Ltd., and Perrigo Company plc leading the sector. These domestic firms not only cater to local demand but also export products globally. Other emerging markets, such as South Korea and Turkey, are also increasing their exports to Israel, contributing to the competitive landscape. While specific market share data is limited, the presence of these diverse suppliers indicates a competitive environment in Israel's pharmaceutical sector.
India's pharmaceutical industry offers several competitive advantages in the Israeli market. The country's cost competitiveness is notable, with pharmaceutical exports valued at $30.47 billion in 2024-25, reflecting a 9.4% growth over the previous year. India's adherence to WHO-GMP standards ensures that its pharmaceutical products meet international quality benchmarks. The widespread use of English facilitates effective communication and collaboration with Israeli partners. Additionally, India's broad portfolio encompasses a wide range of pharmaceutical formulations, catering to various therapeutic areas and patient needs.
Despite its strengths, India faces challenges in the Israeli pharmaceutical market. Regulatory tightening in Israel, including stringent compliance with EU-recognized Good Manufacturing Practices (GMP), can pose barriers for Indian exporters. Competition from Chinese manufacturers, who often offer lower-priced alternatives, intensifies market pressures. Furthermore, perceptions regarding the quality of Indian pharmaceuticals may affect their acceptance among Israeli consumers and healthcare providers. Addressing these challenges requires continuous improvement in product quality, compliance with international standards, and strategic market positioning.
India exported pharmaceuticals worth $22.7M to Israel across 1,068 verified shipments.
1. MEDOPHARM — $9.5M. 2. AUROBINDO PHARMA LTD — $3.8M. 3. JUBILANT GENERICS LIMITED — $1.2M. Total: 94 suppliers.
1. M/S. UNRWA - HEAD FIELD LOGISTICS O — $8.8M. 2. TEVA ISRAEL LTD, — $2.2M. 3. INOVAMED LTD, — $1.4M. 170 buyers total.
1. Amoxicillin and Clavulanate Potassium Fo ($8.9M, 39.0%); 2. Amoxicillin & Clavulanate Potassiumtable ($983.8K, 4.3%); 3. Compresso Pap 96p ($404.9K, 1.8%); 4. Dtp-hepb-hib (pentavalent Vaccine) Fullyliquid Combination Vaccine 10 Dose Vial… ($340.5K, 1.5%); 5. Bortezomib Taro Injection 3.5mg ($246.5K, 1.1%)
Export: CHENNAI AIR, HYDERABAD ICD, HYDERABAD ICD (INSNF6), NHAVA SHEVA SEA (INNSA1), SAHAR AIR CARGO ACC (INBOM4). Import: Ashdod, TEL AVIV YAFO, HAIFA, ASHDOD, Haifa.
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $22.7M corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$21.3K per consignment across 1,068 shipments.
94 Indian companies. Largest: MEDOPHARM with $9.5M.
TransData Nexus covers 94 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 1,068 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
94 Exporters
170 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists